-
1.发明申请Treatment of egfr-dependent tumors by abin (a20 -binding inhibitor of nf kappab) 失效通过abin（nf-kappab的a20结合抑制剂）治疗egfr依赖性肿瘤公开(公告)号：US20090023650A1
公开(公告)日：2009-01-22
申请号：US11918559
申请日：2006-04-11
Applicant: Rudi Beyaert , Hilde Revets , Lieven Huang
Inventor： Rudi Beyaert , Hilde Revets , Lieven Huang
CPC classification number: A61K38/1709
Abstract: The present invention relates to the treatment of epidermal growth factor-family receptor- (ErbB-) dependent tumors. More specifically, the present invention relates to the use of ABIN for the preparation of a medicament to inhibit epidermal growth factor- (EGF-) induced proliferation, and to treat ErbB-dependent tumors.
Abstract translation: 本发明涉及治疗表皮生长因子家族受体（ErbB）依赖性肿瘤。 更具体地，本发明涉及ABIN用于制备抑制表皮生长因子（EGF））诱导的增殖并且治疗ErbB依赖性肿瘤的药物的用途。
-
2.发明申请Use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells 审中-公开使用多肽结构域来调节癌细胞的致瘤和转移潜能公开(公告)号：US20080199472A1
公开(公告)日：2008-08-21
申请号：US12070239
申请日：2008-02-14
Applicant: Hilde Revets , Patrick De Baetselier , Nick Devoogdt , Gholamreza Hassanzadeh Ghassabeh
IPC: A61K39/395 , A61K38/00 , C12N5/06 , A61P43/00 , C12Q1/68
CPC classification number: A61K38/57
Abstract: The present invention reates to the use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells. More specifically, the present invention relates to a domain of a Secretory Leukocyte Protease Inhibitor (SLPI) to modulate tumor invasiveness and/or metastasis. It further relates to compounds, such as antibodies, that interact with the domain and repress the tumor invasiveness and/or the metastasis.
Abstract translation: 本发明涉及使用多肽结构域来调节癌细胞的致瘤和转移潜能。 更具体地，本发明涉及调节肿瘤侵袭和/或转移的分泌性白细胞蛋白酶抑制剂（SLPI）的结构域。 它还涉及与结构域相互作用并抑制肿瘤侵袭和/或转移的化合物，例如抗体。
-
Patent Agency Ranking
3.发明申请Use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells 审中-公开使用多肽结构域来调节癌细胞的致瘤和转移潜能公开(公告)号：US20060111294A1
公开(公告)日：2006-05-25
申请号：US11269070
申请日：2005-11-07
Applicant: Hilde Revets , Patrick De Baetselier , Nick Devoogdt , Gholamreza Hassanzadeh Ghassabeh
IPC: A61K38/17 , G01N33/574
CPC classification number: A61K38/57
Abstract: The present invention relates to the use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells. More specifically, the present invention relates to a domain of a Secretory Leukocyte Protease Inhibitor (SLPI) to modulate tumor invasiveness and/or metastasis. It further relates to compounds, such as antibodies, that interact with said domain and repress the tumor invasiveness and/or the metastasis.
Abstract translation: 本发明涉及多肽结构域用于调节癌细胞的致瘤和转移潜力的用途。 更具体地，本发明涉及调节肿瘤侵袭和/或转移的分泌性白细胞蛋白酶抑制剂（SLPI）的结构域。 它还涉及与所述结构域相互作用并抑制肿瘤侵袭和/或转移的化合物，例如抗体。
-
4.发明授权Treatment of EGFR-dependent tumors by ABIN (a20 -binding inhibitor of NF kappab) 失效通过ABIN（NF-kappab的a20-结合抑制剂）治疗EGFR依赖性肿瘤公开(公告)号：US07893026B2
公开(公告)日：2011-02-22
申请号：US11918559
申请日：2006-04-11
Applicant: Rudi Beyaert , Hilde Revets , Lieven Huang
Inventor： Rudi Beyaert , Hilde Revets , Lieven Huang
IPC: A61K38/00
CPC classification number: A61K38/1709
Abstract: The present invention relates to the treatment of epidermal growth factor-family receptor- (ErbB-) dependent tumors. More specifically, the present invention relates to the use of ABIN for the preparation of a medicament to inhibit epidermal growth factor- (EGF-) induced proliferation, and to treat ErbB-dependent tumors.
Abstract translation: 本发明涉及治疗表皮生长因子家族受体（ErbB）依赖性肿瘤。 更具体地，本发明涉及ABIN用于制备抑制表皮生长因子（EGF））诱导的增殖并且治疗ErbB依赖性肿瘤的药物的用途。
-
公开(公告)号：US06936263B2
公开(公告)日：2005-08-30
申请号：US10222100
申请日：2002-08-16
Applicant: Hilde Revets , Pierre Cornelis , Patrick De Baetselier
Inventor： Hilde Revets , Pierre Cornelis , Patrick De Baetselier
IPC: A61K39/39 , A61P37/04 , C07K14/21 , C07K14/44 , C07K16/10 , A61K39/00 , A61K39/38 , A61K39/385 , A61K39/02 , A61K39/108 , A61K38/00 , A61K9/127 , C12N1/12 , C12P1/00 , C12P21/04
CPC classification number: A61K39/39 , A61K2039/523 , A61K2039/55544 , A61K2039/57 , C07K14/21 , C07K14/44 , C07K16/10 , C07K2319/00 , Y02A50/41 , Y10S424/823 , Y10S424/824 , Y10S424/825 , Y10S424/826 , Y10S424/828 , Y10S424/829
Abstract: The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of OprI—antigen fusion proteins to elicit the Type-1 response. More particularly, the present invention is directed to pharmaceutical formulations comprising OprI and/or OprI fusion proteins, optionally together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.
Abstract translation: 本发明涉及铜绿假单胞菌的主要OprI脂蛋白对异源抗原引起1型免疫应答的用途。 本发明具体涉及使用OprI-抗原融合蛋白引起1型反应。 更具体地，本发明涉及包含OprI和/或OprI融合蛋白的药物制剂，任选与合适的赋形剂一起刺激Th1依赖性细胞免疫应答。
-
公开(公告)号：US20050048060A1
公开(公告)日：2005-03-03
申请号：US10885492
申请日：2004-07-06
Applicant: Hilde Revets , Virna Cortez-Retamozo , Serge Muyldermans , Patrick De Baetselier
Inventor： Hilde Revets , Virna Cortez-Retamozo , Serge Muyldermans , Patrick De Baetselier
IPC: A61K47/48 , A61P35/00 , A61K39/395 , C07K16/30
CPC classification number: B82Y5/00 , A61K47/6853 , A61K47/6899
Abstract: The present invention relates to novel immunoconjugates that are devoid of light chains and comprise at least one variable domain of a heavy chain antibody. The immunoconjugates of the present invention can be used, for example, for the preparation of a medicament to treat tumors.
Abstract translation: 本发明涉及不含轻链的新型免疫偶联物，并且包含至少一个可变结构域的重链抗体。 本发明的免疫偶联物可用于例如制备治疗肿瘤的药物。
-
公开(公告)号：US20070031430A1
公开(公告)日：2007-02-08
申请号：US11542714
申请日：2006-10-04
Applicant: Hilde Revets , Virna Cortez-Retamozo , Serge Muyldermans , Patrick De Baetselier
Inventor： Hilde Revets , Virna Cortez-Retamozo , Serge Muyldermans , Patrick De Baetselier
IPC: A61K39/395 , C12N9/00 , C07K16/30
CPC classification number: B82Y5/00 , A61K47/6853 , A61K47/6899
Abstract: The present invention relates to novel immunoconjugates that are devoid of light chains and comprise at least one variable domain of a heavy chain antibody. The immunoconjugates of the present invention can be used for the preparation of a medicament to treat tumours.
Abstract translation: 本发明涉及不含轻链的新型免疫偶联物，并且包含至少一个可变结构域的重链抗体。 本发明的免疫偶联物可用于制备治疗肿瘤的药物。
-
-
-
-
-
-
Search Results
7
records
(took 0.008 seconds)
